Biovest study backs non-Hodgkin

http://financeservicesnews.com/company-valuation-property-owning-companies.htm
The study was featured at the ’s annuak meeting in Orlando, Biovest said in a release. It is a brighyt spot for Biovest and itsparent company, (PINK SHEETS: which filed for Chapterr 11 bankruptcy late last year. BiovaxIxD is a personalized therapeutic anti-cancer vaccine individually manufactured from a tissu e biopsy obtained froma patient’s own selectively targeting only the cancerous B-cell s while sparing health cells. The study foun d that patients who received BiovaxIDD experienced amedian disease-free survivalo of 44.2 month, compared to 30.6 months for those who receiv e a control vaccine, an increase of 47 In follow-ups with a median of 4.
7 patients receiving BiovaxID experienced a 38 percent lower risk of diseaser recurrence compared to patients receiving the controll vaccine. BiovaxID is the first vaccinse targeting lymphoma to demonstrate sucha disease-free surviva l benefit, the release said. Biovest (PINK SHEETS: BVTI) has initiaterd discussions with the and the to determine the most appropriateeregulatory pathways, Samuel president and general counsel of Biovest, said in the The company also plans to make the vaccinew available throughout most of Europes through a compassionate use drug access progra that allows European physicianz to prescribe drugs to qualifying patients before approvals are Both Accentia (PINK SHEETS: ABPIQ), a drug development firm, and Biovest are headquartered in Tampa.